a Department of Ophthalmology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine , University of Science and Technology of China , Hefei , Anhui , P.R. China.
b Department of Ophthalmology , Wannan Medical College , Wuhu , Anhui , China.
Curr Eye Res. 2019 Jul;44(7):739-745. doi: 10.1080/02713683.2019.1588331. Epub 2019 Mar 29.
: After experimental retinal detachment (RD), the applications of caspase inhibitor z-vad-fmk (a pan-caspase inhibitor) could inhibit apoptosis, but increased receptor interacting protein (RIP)-mediated necroptosis. In this study, we investigated whether rapamycin could inhibit necroptosis and cooperate with z-vad-fmk to protect the retina after RD. : RD animal models were established in Sprague-Dawley rats by subretinal injection of sodium hyaluronate and treated with subretinal injections of z-vad-fmk or z-vad-fmk combined with rapamycin. On day 3 after RD, retinas were collected and analyzed by transmission electron microscopy (TEM), ROS assay, and western blot (for beclin-1, LC-3, RIP-1, AIF). On day 7 after RD, retinas were observed by H&E staining. Vision-dependent behavior of rats was tested by the modified Morris water maze. : TEM and H&E staining indicated that rapamycin combined with z-vad-fmk could reduce photoreceptor necrosis and preserve the ONL thickness after RD. The modified Morris water maze test showed that vision-dependent behavior was also significantly improved in the rapamycin + z-vad-fmk group.Western Blotting results demonstrated that rapamycin promoted the activation of autophagy by promoting beclin-1 and LC-3 induction and inhibited z-vad-fmk-induced necroptosis by inhibiting RIP-1 expression. In addition, rapamycin could also inhibit ROS production and AIF release. : These findings indicated that rapamycin is a promising therapeutic agent that inhibits z-VAD-induced necroptosis, and protects photoreceptors and improves functional outcome in combination with z-vad-fmk.
实验性视网膜脱离(RD)后,应用半胱天冬酶抑制剂 z-vad-fmk(一种半胱天冬酶抑制剂)可抑制细胞凋亡,但会增加受体相互作用蛋白(RIP)介导的坏死性凋亡。本研究旨在探讨雷帕霉素是否能抑制坏死性凋亡,并与 z-vad-fmk 联合保护 RD 后的视网膜。
通过玻璃体内注射透明质酸钠在 Sprague-Dawley 大鼠中建立 RD 动物模型,并通过玻璃体内注射 z-vad-fmk 或 z-vad-fmk 联合雷帕霉素进行处理。RD 后第 3 天,收集视网膜并通过透射电子显微镜(TEM)、ROS 测定和 Western blot(检测 beclin-1、LC-3、RIP-1、AIF)进行分析。RD 后第 7 天,通过 H&E 染色观察视网膜。通过改良 Morris 水迷宫测试检测大鼠的视觉相关行为。
TEM 和 H&E 染色表明,雷帕霉素联合 z-vad-fmk 可减少 RD 后光感受器坏死并保留 ONL 厚度。改良 Morris 水迷宫测试表明,雷帕霉素+z-vad-fmk 组的视觉相关行为也显著改善。Western blot 结果表明,雷帕霉素通过促进 beclin-1 和 LC-3 的诱导来促进自噬的激活,并通过抑制 RIP-1 的表达来抑制 z-vad-fmk 诱导的坏死性凋亡。此外,雷帕霉素还可以抑制 ROS 产生和 AIF 释放。
这些发现表明,雷帕霉素是一种有前途的治疗药物,可抑制 z-VAD 诱导的坏死性凋亡,并与 z-vad-fmk 联合保护光感受器并改善功能结局。